Voyager Therapeutics, INC. (VYGR) — 10-Q Filings

All 10-Q filings from Voyager Therapeutics, INC.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (5)

Voyager's Losses Mount Amid Plummeting Collaboration Revenue — Nov 10, 2025 Risk: high
Voyager Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $92.295 million, a substantial ris
Voyager's Q2 Loss Widens Amid R&D Surge — Aug 6, 2025 Risk: high
Voyager Therapeutics, Inc. reported a net loss of $29.5 million for the three months ended June 30, 2025, a significant increase from the net loss of $20.1 mill
Voyager Therapeutics Q3 2024 Update — Nov 12, 2024 Risk: medium
Voyager Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported cash and cash equivalents of $178.4 million as of Septe
Voyager Therapeutics Q2 2024 Update — Aug 6, 2024 Risk: medium
Voyager Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported cash and cash equivalents of $54.5 million as of June 30, 20
Voyager Therapeutics Reports Q1 2024 Results, Focus on Gene Therapy Development — May 13, 2024 Risk: medium
Voyager Therapeutics, Inc. (VYGR) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Voyager Therapeutics reported Q1 2024 results on May 13, 2024. T

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX